Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 197

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 197
---
 us or would involve providing
services to our competitors. See “Management— Engagement Agreements with Executive
Officers” for additional information.

Investors’ Rights Agreement

On
February 5, 2016, we entered into an investors’ rights agreement, or
the IRA, with several of our shareholders, who hold in the aggregate a total of 2,365,980
Ordinary Shares. Pursuant to the IRA, the shareholders have a right to require that we register
such 2,365,980 Ordinary Shares under the Securities Act under specific circumstances and
will have incidental registration rights as described below. On March 20,
2025, our shareholders approved the termination of the IRA subject to the completion of this
offering. Accordingly, the IRA will be of no further effect thereafter.

<div align='center'>115

DESCRIPTION OF SHARE CAPITAL</div>

The following description
of our share capital and provisions of our amended and restated articles of association which will be effective upon the completion of
this offering are summaries and do not purport to be complete. By becoming a shareholder in our Company, you will be deemed to have notice
of and consented to these provisions of our articles of association as amended and restated.

Authorized Capital

Upon the closing of this
offering, our authorized share capital will consist of 22,500,000 Ordinary Shares, no par value per share, of which Ordinary Shares will
be issued and outstanding (assuming that the Representative does not exercise its option to purchase additional Ordinary Shares).

All of our Ordinary Shares
have identical voting and other rights in all respects. All of our issued and outstanding Ordinary Shares are duly authorized, validly
issued, fully paid and non-assessable. Our amended and restated articles of association to be in effect upon completion of this offering
and the laws of the State of Israel do not restrict the ownership or voting of Ordinary Shares by non-residents of Israel, except with
respect to citizens of countries that are, or have been, in a state of war with Israel.

Preferred Shares

Upon the consummation of this
offering and the effectiveness of our amended and restated certificate of incorporation that will become effective immediately prior to
the consummation of this offering, we will have no authorized or outstanding preferred shares.

Each currently outstanding
Series A Preferred Share, Series B Preferred Share, Series C Preferred Share, Series D-1 Preferred Share and Series D-2 Preferred Share,
each a Preferred Share, is convertible,